期刊文献+

两性霉素B与两性霉素B脂质体治疗真菌感染的疗效比较 被引量:17

两性霉素B与两性霉素B脂质体治疗真菌感染的疗效比较
下载PDF
导出
摘要 目的观察两性霉素B与两性霉素B脂质体对恶性血液病患者侵袭性真菌感染的临床疗效及不良反应。方法回顾用两性霉素B与两性霉素B脂质体治疗恶性血液病合并侵袭性真菌感染病例。A组:(两性霉素B组20例),B组(:两性霉素B脂质体组19例)。结果临床总有效率A组为75.0%,B组84.2%,;A组不良反应畏寒、寒战、发热,低血钾血症,消化道反应,肾功能损害,肝功损害及静脉炎的发生率分别为55.0%、45.0%、20.0%、15.0%、10.0%、10.0%;B组分别为5.2%、26.3%、10.5%、5.2%、5.2%、5.2%。结论两性霉素B脂质体较两性霉素B疗效略高,两性霉素B副作用较两性霉素B脂质体大,但两性霉素B价格便宜,是治疗侵袭性真菌感染比较安全有效、经济的选择。 Objective To compare the therapeutic effect and side effects of conventional between amphotericin B and liposomal amphotericin B in thetreatment of invasive fungal infections(IFI) in immunocompromised patients. Methods We retrospectively analyzed 39 diagnosed patients with invasive fungal infections(IFI) in immunocompromised patients who treated in our hospital.20cases in A group were treated with amphotericin B while 19 cases in B group were treated with liposomal amphotericin B.Results The Clinical efficacy rate of amphotericin B was 75. 7%, while efficacy rate of liposomal amphotericin B was 84.2%.A group the side effects of conventional such as chill,hypokalemia, gastrointestinal symptoms, kidney damage ,hepatic damage were 55.0% 45.0%,20.0%,15.0%,10.0%,10.0% while B group were 5.2% 26.3% 10.5% 5.2% 5.2% 5.2%. Conclusion Liposomal amphotericin B is more effective,while there is liter side-effects but amphotericin B is more cheaper than liposomal amphotericin B. Conventional amphotericin B is effective and less expensive and safe in treatment .
作者 张静 徐敬根
出处 《当代医学》 2011年第9期102-103,共2页 Contemporary Medicine
关键词 两性霉素B 两性霉素B脂质 侵袭性真菌感染 Amphotericin B Liposomal amphotericin B Invasive fungal infections(IFI)
  • 相关文献

参考文献4

二级参考文献9

  • 1黄晓军.血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(草案)[J].中华内科杂志,2005,44(7):554-556. 被引量:423
  • 2王景枝,刘代红,许兰平,陈欢,刘开彦,黄晓军.伊曲康唑在异基因造血干细胞移植患者真菌感染中的应用[J].中华内科杂志,2007,46(1):29-31. 被引量:7
  • 3Ellis M.Invasive fungal infections:evolving challenges for diagnosis and therapeutics[J].Mol Immunol,2001,38:947-957. 被引量:1
  • 4Kieren AM,Thomas P,David D,et al.Aspergillosis:pathogenesis,clinical manifestation and therapy[J].Infect Dis Clin N Am,2002,16:875-894. 被引量:1
  • 5Ostroskky-ZeichnerL.New approaches to the risk of candida in the intensive care unit[J].Curr Opin Infect Dis,2003,16:533-537. 被引量:1
  • 6Wong-beringer A,Kriengkauykiat J.Systemic antifungal therapy:new options,new challenges[J].Pharmacotherapy,2003,23:1441-1462. 被引量:1
  • 7Herbrecht R,Denning DW,Patterson TF,et al.Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.N EnglJ Med,2002,347:408-415. 被引量:1
  • 8Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis, 2002, 34: 7-14. 被引量:1
  • 9Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of fungal infections in hematology and oncology-guidelines of the Infectious Diseases Working Party (AG1HO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol, 2003, 82 Suppl 2 :S133-S140. 被引量:1

共引文献265

同被引文献158

引证文献17

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部